Buntanetap tartrate is under clinical development by Annovis Bio and currently in the Phase I and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Buntanetap tartrate’s likelihood of approval (LoA) and phase transition for Dementia Associated With Alzheimer’s Disease took place on 27 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Buntanetap tartrate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Buntanetap tartrate overview

Buntanetap (ANVS-401 (Posiphen)) is under development for the treatment of Alzheimer's disease, Parkinson's disease, Down syndrome in Alzheimer's disease, frontotemporal dementia (FTD) and chronic traumatic encephalopathy (CTE). The drug candidate is the enantiomer of phenserine. It is administered through oral route. It acts by targeting amyloid precursor protein (APP), tau and alpha-synuclein.

It was also under development for the treatment of Huntington’s disease and traumatic brain injury. 

Annovis Bio overview

Annovis Bio is a clinical-stage drug platform company that carries out the development of novel drugs for the treatment of various diseases. The company’s pipeline products include buntanetap, to treat parkinson’s disease (PD), alzheimer’s disease (AD), and other chronic neurodegenerative diseases; ANVS405, to treat traumatic brain injury (TBI) and stroke; ANVS301, to treat advanced alzheimer’s disease. It provides drug candidates in oral and injectable forms. Annovis Bio also carries out preclinical animal studies and clinical trials. The company collaborates with contractor laboratories, independent contractors and contract research organizations. Annovis Bio is headquartered in Berwyn, Pennsylvania, the US.

Quick View Buntanetap tartrate LOA Data

Report Segments
  • Innovator
Drug Name
  • Buntanetap tartrate
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Developers
  • Sponsor Company: Annovis Bio
  • Originator: U.S. National Institutes of Health
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.